Characteristics | Patients | Tumoral CCR7 expression | |||
---|---|---|---|---|---|
n | % | low | high | P-value | |
No. of patients | 110 | 100 | 53 | 57 | |
Age, years, mean (SD) | 57.5 (11.9) | ||||
Men | 79 | 71.8 | |||
ECOG PS | 0.198c | ||||
0 | 81 | 73.6 | 42 | 39 | |
1 | 29 | 26.4 | 11 | 18 | |
Prior nephrectomy | N/A | ||||
Yes | 110 | 100.0 | |||
No | 0 | 0.0 | |||
Histology | 0.086c | ||||
Clear cell | 88 | 80.0 | 46 | 42 | |
Non-clear cell type | 22 | 20.0 | 7 | 15 | |
Papillary | 15 | 13.6 | |||
Chromophobe | 2 | 1.8 | |||
Collecting duct | 2 | 1.8 | |||
Unclassified | 3 | 2.7 | |||
Fuhrman grade (7 excluded) | 0.147d | ||||
1 | 2 | 1.8 | 2 | 0 | |
2 | 53 | 48.2 | 28 | 25 | |
3 | 41 | 37.3 | 18 | 23 | |
4 | 7 | 6.4 | 5 | 2 | |
TNM stage at initial diagnosis | 0.004 c | ||||
I-III | 51 | 46.4 | 32 | 19 | |
IV | 59 | 53.6 | 21 | 38 | |
Site of metastatic diseasea | |||||
Lung | 82 | 74.5 | |||
Liver | 13 | 11.8 | |||
Bone | 18 | 16.4 | |||
Lymph node | 29 | 26.4 | |||
Adrenal gland | 8 | 7.3 | |||
Brain and others | 15 | 13.6 | |||
Lymph node involvementa | 0.031 c | ||||
No | 81 | 73.6 | 44 | 37 | |
Yes | 29 | 26.4 | 9 | 20 | |
No. of metastatic sitesa | 0.070c | ||||
1 | 76 | 69.1 | 41 | 35 | |
≥ 2 | 34 | 30.9 | 12 | 22 | |
Tyrosine kinase inhibitors | 0.254c | ||||
Sunitinib | 73 | 66.4 | 38 | 35 | |
Sorafenib | 37 | 33.6 | 15 | 22 | |
Heng’s risk group | 0.271d | ||||
Favorable | 22 | 20 | 12 | 10 | |
Intermediate | 60 | 54.5 | 30 | 30 | |
Poor | 28 | 25.5 | 11 | 17 | |
Best response (3 not assessable) | <0.001 d | ||||
Partial response | 27 | 25.2 | 18 | 9 | |
Stable disease for ≥3 months | 57 | 53.3 | 30 | 27 | |
Progressive diseaseb | 23 | 21.5 | 2 | 21 |